Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Chromatics Color Sciences International. Inc; CCSI -- Ignore unavailable to you. Want to Upgrade?

To: Peter V who wrote (4246)	7/20/1998 1:53:00 PM
From: Dixie7777	Read Replies (1) \| Respond to of 5736

As you have just "phrased" it, not much. In context of the attendant PR's and informational intent by all parties to the PR, a world of difference. Make your calls, or are you also physically challenged?

To: Peter V who wrote (4246)	7/20/1998 3:26:00 PM
From: Cacaito	Read Replies (3) \| Respond to of 5736

Peter V, the way I interpret Maisels,s opinion, especially with the Nelcor pulse oximeter comparison: the "multicenter" studies will be done and many of this studies will not be by the company but buy independent clinicians to prove the value of the new device .It is done with every single new drug and device, and many wait for this non company study to buy the product. That the company (or Maisels on his own) conduct post-marketing studies is not rare, some areas of applications were probably not covered initially ( for example: very small premature babies, or infants older than 2 weeks). Look at today's news on Genentech drug for strokes (it is proven within 3 hours to be beneficial) they were trying to prove the same after 3 hours (it will double or triple the market) and it did not work. The "multicenter" studies Maisels referred to will not be needed for the initial selling of the device (if the marketing partner comes around), they are already approved, they only need the buyers, not more studies.